Grants Search Results

Diffuse midline glioma is a devastating disease with no known curative therapy. New treatments using immunotherapy approaches, like CAR T therapy, show promise; however, tumors often escape detection by hiding their target proteins and suppressing the immune response to therapy. Dr. Pomaville seeks to tackle this problem by manipulating RNA modifications in the tumor and body to improve response to CAR T therapy. She has found that drugs that mediate RNA methylation, the most common modification on protein-coding mRNA, increases protein levels of existing CAR T antigens and can induce cell death. This RNA modification mark also influences how the body's immune system responds to tumors. Dr. Pomaville will test this drug in cell-line and immunocompetent models to assess whether manipulation of RNA methylation leads to improved efficacy of CAR T therapy. Dr. Pomaville and team will develop combination strategies that enhance the response to immunotherapy in patients.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.